Drug Profile

Research programme: norepinephrine reuptake inhibitors - Supernus Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Unknown
Developer Supernus Pharmaceuticals
Class 3-ring heterocyclic compounds; Anorectics; Behavioural disorder therapies; Drug withdrawal therapies; Imidazoles; Isoindoles; Sleep disorder therapies; Small molecules
Mechanism of Action Adrenergic receptor agonists; Adrenergic receptor antagonists; Dopamine uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

16 Jul 2016 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA (PO)
29 Jul 2009 Early research in Attention-deficit hyperactivity disorder in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com